Abstract
Summary
LPI (LP Information)' newest research report, the “Anti–vascular Endothelial Growth Factor Therapy Industry Forecast” looks at past sales and reviews total world Anti–vascular Endothelial Growth Factor Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti–vascular Endothelial Growth Factor Therapy sales for 2023 through 2029. With Anti–vascular Endothelial Growth Factor Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti–vascular Endothelial Growth Factor Therapy industry.
This Insight Report provides a comprehensive analysis of the global Anti–vascular Endothelial Growth Factor Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti–vascular Endothelial Growth Factor Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti–vascular Endothelial Growth Factor Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti–vascular Endothelial Growth Factor Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti–vascular Endothelial Growth Factor Therapy.
The global Anti–vascular Endothelial Growth Factor Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Anti–vascular Endothelial Growth Factor Therapy players cover Regeneron Pharmaceuticals (Eylea), Genentech and Kanghong Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti–vascular Endothelial Growth Factor Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Extraction Injection
Precharge Injection
Segmentation by application
Macular Degeneration
Nacular Edema
Uveitis
Retinal Vein Occlusion
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Genentech
Kanghong Pharmaceutical
This Insight Report provides a comprehensive analysis of the global Anti–vascular Endothelial Growth Factor Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti–vascular Endothelial Growth Factor Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti–vascular Endothelial Growth Factor Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti–vascular Endothelial Growth Factor Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti–vascular Endothelial Growth Factor Therapy.
The global Anti–vascular Endothelial Growth Factor Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Anti–vascular Endothelial Growth Factor Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Anti–vascular Endothelial Growth Factor Therapy players cover Regeneron Pharmaceuticals (Eylea), Genentech and Kanghong Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti–vascular Endothelial Growth Factor Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Extraction Injection
Precharge Injection
Segmentation by application
Macular Degeneration
Nacular Edema
Uveitis
Retinal Vein Occlusion
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Genentech
Kanghong Pharmaceutical
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti–vascular Endothelial Growth Factor Therapy Market Size 2018-2029
2.1.2 Anti–vascular Endothelial Growth Factor Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Anti–vascular Endothelial Growth Factor Therapy Segment by Type
2.2.1 Extraction Injection
2.2.2 Precharge Injection
2.3 Anti–vascular Endothelial Growth Factor Therapy Market Size by Type
2.3.1 Anti–vascular Endothelial Growth Factor Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Anti–vascular Endothelial Growth Factor Therapy Market Size Market Share by Type (2018-2023)
2.4 Anti–vascular Endothelial Growth Factor Therapy Segment by Application
2.4.1 Macular Degeneration
2.4.2 Nacular Edema
2.4.3 Uveitis
2.4.4 Retinal Vein Occlusion
2.5 Anti–vascular Endothelial Growth Factor Therapy Market Size by Application
2.5.1 Anti–vascular Endothelial Growth Factor Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Anti–vascular Endothelial Growth Factor Therapy Market Size Market Share by Application (2018-2023)
3 Anti–vascular Endothelial Growth Factor Therapy Market Size by Player
3.1 Anti–vascular Endothelial Growth Factor Therapy Market Size Market Share by Players
3.1.1 Global Anti–vascular Endothelial Growth Factor Therapy Revenue by Players (2018-2023)
3.1.2 Global Anti–vascular Endothelial Growth Factor Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Anti–vascular Endothelial Growth Factor Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Anti–vascular Endothelial Growth Factor Therapy by Regions
4.1 Anti–vascular Endothelial Growth Factor Therapy Market Size by Regions (2018-2023)
4.2 Americas Anti–vascular Endothelial Growth Factor Therapy Market Size Growth (2018-2023)
4.3 APAC Anti–vascular Endothelial Growth Factor Therapy Market Size Growth (2018-2023)
4.4 Europe Anti–vascular Endothelial Growth Factor Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy Market Size Growth (2018-2023)
5 Americas
5.1 Americas Anti–vascular Endothelial Growth Factor Therapy Market Size by Country (2018-2023)
5.2 Americas Anti–vascular Endothelial Growth Factor Therapy Market Size by Type (2018-2023)
5.3 Americas Anti–vascular Endothelial Growth Factor Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti–vascular Endothelial Growth Factor Therapy Market Size by Region (2018-2023)
6.2 APAC Anti–vascular Endothelial Growth Factor Therapy Market Size by Type (2018-2023)
6.3 APAC Anti–vascular Endothelial Growth Factor Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Anti–vascular Endothelial Growth Factor Therapy by Country (2018-2023)
7.2 Europe Anti–vascular Endothelial Growth Factor Therapy Market Size by Type (2018-2023)
7.3 Europe Anti–vascular Endothelial Growth Factor Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy by Region (2018-2023)
8.2 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.1 Global Anti–vascular Endothelial Growth Factor Therapy Forecast by Regions (2024-2029)
10.1.1 Global Anti–vascular Endothelial Growth Factor Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Anti–vascular Endothelial Growth Factor Therapy Forecast
10.1.3 APAC Anti–vascular Endothelial Growth Factor Therapy Forecast
10.1.4 Europe Anti–vascular Endothelial Growth Factor Therapy Forecast
10.1.5 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy Forecast
10.2 Americas Anti–vascular Endothelial Growth Factor Therapy Forecast by Country (2024-2029)
10.2.1 United States Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.2.2 Canada Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.2.3 Mexico Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.2.4 Brazil Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3 APAC Anti–vascular Endothelial Growth Factor Therapy Forecast by Region (2024-2029)
10.3.1 China Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3.2 Japan Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3.3 Korea Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3.4 Southeast Asia Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3.5 India Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.3.6 Australia Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.4 Europe Anti–vascular Endothelial Growth Factor Therapy Forecast by Country (2024-2029)
10.4.1 Germany Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.4.2 France Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.4.3 UK Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.4.4 Italy Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.4.5 Russia Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.5 Middle East & Africa Anti–vascular Endothelial Growth Factor Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.5.2 South Africa Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.5.3 Israel Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.5.4 Turkey Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.5.5 GCC Countries Anti–vascular Endothelial Growth Factor Therapy Market Forecast
10.6 Global Anti–vascular Endothelial Growth Factor Therapy Forecast by Type (2024-2029)
10.7 Global Anti–vascular Endothelial Growth Factor Therapy Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Regeneron Pharmaceuticals (Eylea)
11.1.1 Regeneron Pharmaceuticals (Eylea) Company Information
11.1.2 Regeneron Pharmaceuticals (Eylea) Anti–vascular Endothelial Growth Factor Therapy Product Offered
11.1.3 Regeneron Pharmaceuticals (Eylea) Anti–vascular Endothelial Growth Factor Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Regeneron Pharmaceuticals (Eylea) Main Business Overview
11.1.5 Regeneron Pharmaceuticals (Eylea) Latest Developments
11.2 Genentech
11.2.1 Genentech Company Information
11.2.2 Genentech Anti–vascular Endothelial Growth Factor Therapy Product Offered
11.2.3 Genentech Anti–vascular Endothelial Growth Factor Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Genentech Main Business Overview
11.2.5 Genentech Latest Developments
11.3 Kanghong Pharmaceutical
11.3.1 Kanghong Pharmaceutical Company Information
11.3.2 Kanghong Pharmaceutical Anti–vascular Endothelial Growth Factor Therapy Product Offered
11.3.3 Kanghong Pharmaceutical Anti–vascular Endothelial Growth Factor Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Kanghong Pharmaceutical Main Business Overview
11.3.5 Kanghong Pharmaceutical Latest Developments
12 Research Findings and Conclusion